EMA Authorised: Krazati (adagrasib) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Krazati (adagrasib) for non-small cell lung cancer under conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KRAZATI (adagrasib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 17/11/2025. Conditional approval